Zurcher Kantonalbank Zurich Cantonalbank Has $2.33 Million Position in Charles River Laboratories International, Inc. (NYSE:CRL)

Zurcher Kantonalbank Zurich Cantonalbank decreased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 66.9% in the fourth quarter, HoldingsChannel reports. The institutional investor owned 9,858 shares of the medical research company’s stock after selling 19,911 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Charles River Laboratories International were worth $2,330,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the business. VisionPoint Advisory Group LLC lifted its stake in Charles River Laboratories International by 105.7% during the third quarter. VisionPoint Advisory Group LLC now owns 144 shares of the medical research company’s stock worth $28,000 after purchasing an additional 74 shares during the period. Headlands Technologies LLC acquired a new position in Charles River Laboratories International during the third quarter worth $37,000. Operose Advisors LLC bought a new position in shares of Charles River Laboratories International during the third quarter valued at $42,000. Venturi Wealth Management LLC boosted its stake in shares of Charles River Laboratories International by 74.7% in the 3rd quarter. Venturi Wealth Management LLC now owns 262 shares of the medical research company’s stock valued at $51,000 after purchasing an additional 112 shares in the last quarter. Finally, Provence Wealth Management Group bought a new stake in shares of Charles River Laboratories International in the 3rd quarter worth about $57,000. 98.91% of the stock is owned by institutional investors.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Victoria L. Creamer sold 5,000 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $253.70, for a total value of $1,268,500.00. Following the transaction, the executive vice president now owns 13,550 shares of the company’s stock, valued at $3,437,635. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, EVP Victoria L. Creamer sold 5,000 shares of the business’s stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $253.70, for a total transaction of $1,268,500.00. Following the completion of the transaction, the executive vice president now owns 13,550 shares in the company, valued at $3,437,635. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Shannon M. Parisotto sold 5,882 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $241.20, for a total transaction of $1,418,738.40. Following the completion of the sale, the executive vice president now directly owns 2,596 shares of the company’s stock, valued at approximately $626,155.20. The disclosure for this sale can be found here. Insiders have sold 14,932 shares of company stock worth $3,693,663 in the last three months. Insiders own 1.30% of the company’s stock.

Charles River Laboratories International Stock Up 3.2 %

Shares of NYSE CRL opened at $239.98 on Wednesday. Charles River Laboratories International, Inc. has a 1 year low of $161.65 and a 1 year high of $275.00. The firm’s 50-day moving average is $254.27 and its 200-day moving average is $222.23. The company has a current ratio of 1.52, a quick ratio of 1.16 and a debt-to-equity ratio of 0.73. The firm has a market capitalization of $12.36 billion, a PE ratio of 26.06, a price-to-earnings-growth ratio of 1.78 and a beta of 1.40.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 14th. The medical research company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.39 by $0.07. Charles River Laboratories International had a net margin of 11.49% and a return on equity of 16.53%. The business had revenue of $1.01 billion for the quarter, compared to analyst estimates of $991.25 million. During the same period in the prior year, the business posted $2.98 earnings per share. Charles River Laboratories International’s revenue was down 7.9% compared to the same quarter last year. Equities analysts expect that Charles River Laboratories International, Inc. will post 11.01 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. UBS Group lifted their price target on shares of Charles River Laboratories International from $270.00 to $290.00 and gave the company a “buy” rating in a report on Thursday, February 15th. Guggenheim downgraded Charles River Laboratories International from a “buy” rating to a “neutral” rating in a report on Thursday, February 15th. Robert W. Baird raised their price target on Charles River Laboratories International from $252.00 to $268.00 and gave the company an “outperform” rating in a report on Thursday, February 15th. JPMorgan Chase & Co. boosted their price objective on Charles River Laboratories International from $270.00 to $280.00 and gave the stock an “overweight” rating in a research note on Thursday, February 15th. Finally, Argus raised their target price on Charles River Laboratories International from $240.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, March 18th. Five investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, Charles River Laboratories International has a consensus rating of “Moderate Buy” and a consensus price target of $253.23.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).